XML 40 R18.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Major Customers, Partnerships and Strategic Alliances (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2015
Biogen Inc [Member] |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement with Biogen for the three months ended March 31, 2015 and 2014 are as follows (in thousands):
|  | Three months ended |
|  | March 31, |
|  | 2015 |  |  | 2014 |
Revenue related to Biogen Collaboration: |  |  |  |  |  |  |  |
Recognition of upfront fee |  | $ | 1,523 |  |  | $ | 660 |
Research services |  |  | 1,533 |  |  |  | 423 |
Total |  | $ | 3,056 |  |  | $ | 1,083 |
Shire AG [Member] |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement with Shire for the three months ended March 31, 2015 and 2014, were as follows (in thousands):
|  | Three months ended |
|  | March 31, |
|  | 2015 |  |  | 2014 |
Revenue related to Shire Collaboration: |  |  |  |  |  |  |  |
Recognition of upfront fee |  | $ | 542 |  |  | $ | 542 |
Research services |  |  | 4,522 |  |  |  | 4,979 |
Total |  | $ | 5,064 |  |  | $ | 5,521 |
Sigma-Aldrich Corporation [Member] |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement with Sigma for the three months ended March 31, 2015 and 2014, were as follows (in thousands):
|  | Three months ended |
|  | March 31, |
|  | 2015 |  |  | 2014 |
Revenue related to Sigma Collaboration: |  |  |  |  |  |  |  |
Royalty revenues |  | $ | 264 |  |  | $ | 106 |
License fee revenues |  |  | 4,256 |  |  |  | 179 |
Total |  | $ | 4,520 |  |  | $ | 285 |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |